Primary outcome
What NCT01755416 measured first
| Closed Loop/Insulinn=15 | Closed Loop/Insulin/Liraglutiden=15 |
|---|---|
| 159.7(50.9) | 144.6(36.3) |
Phase 2 · Liraglutide
NCT01755416 trial results
Phase 1 Study of Medtronic Closed Loop Device With ePID Algorithm and Enlite Sensors on Adjuvant Therapy With Insulin and Liraglutide to Minimize Post-prandial Hyperglycemia
Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone (mg/dl), 0-1500 min. Closed Loop/Insulin: 159.7; Closed Loop/Insulin/Liraglutide: 144.6.
- Participants
- 18
- Status
- completed
- Completed
- 2015-01
- Sponsor
- Albert Einstein College of Medicine
As posted on ClinicalTrials.gov (NCT01755416), updated at source Aug 21, 2018. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.
The trial
How NCT01755416 was run
Hypothesis: In type 1 diabetes mellitus, in the setting of a closed loop glucose control system: adjunctive therapy with Liraglutide will afford better post-prandial glycemic excursions than insulin mono-therapy. Specific Aim: To determine if post-prandial glucose excursions are lowered with the addition of Liraglutide compared to insulin mono-therapy. Study Design: This is a randomized open labeled crossover design trial comparing adjuvant Liraglutide and insulin Vs. insulin mono-therapy using the ePID closed-loop system for insulin delivery.
- Closed loop with sensor and Insulin: subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
- Closed loop with sensor, Insulin and Liraglutide: Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
Who could join the trial
Inclusion Criteria: * Age greater than 18 years and less than 40 years * Have had diabetes for at least 1 year, and in good control (HbA1C \< 8.5 %) * Be on continuous subcutaneous insulin infusion using an insulin pump * Menstruating women must have negative pregnancy test. * Hemoglobin (Hb) \> 12 g/dL * Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 3 months prior to Screening: a. Oral contraceptives (female subjects)b. Antihypertensive agents c. Lipid-lowering agents d. Thyroid replacement therapy e. Antidepressant agents * For female subjects:a. Not breastfeeding b. Negative pregnancy test result (human chorionic gonadotropin, beta subunit \[βhCG\])at Screening c. If of childbearing potential, must practice and be willing to continue to practice appropriate birth control (defined as at least one method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as implants, injectable's, hormonal contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation or occlusion, or a vasectomized partner)during the entire duration of the study and must not be planning to conceive * Should not have any alcohol or drug dependency as assessed by CRAFFT questionnaire. Exclusion Criteria: * Any chronic disease (leukemia, asthma, inflammatory bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, etc., that directly, or as a result of treatment, directly or indirectly affect glucose homeostasis * Hemoglobin less than 12 g/dl * Positive pregnancy test in menstruating young women * Evidence or history of chemical abuse * HbA1c \> 8.5 % * Weight less than 50 Kg * History of gastro paresis and on medications that alter gastric emptying * History of Pancreatitis and impaired renal function * Hypoglycemic unawareness * History of sensitivity to 5-HT3 receptor antagonists * History of QT prolongation or any known cardio-vascular disease * Concomitant use of both Acetaminophen and vitamin C * Patients on glucocorticoid therapy * Known allergy to Liraglutide * Personal or family history of elevated calcitonin, calcitonin \>100 ng/L, medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia (MEN) syndrome type 2.
Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.
GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.